Neimann-Pick Diseases: Beyond Lipid Accumulation – Genetic, Diagnostics, and Therapeutic Strategies

Hind M Naffadi

Abstract


Rare genetic disorders are the group of disorders/diseases that occur in such a low count that they are not considered much active market for therapeutics unless encouraged by appropriate incentives and support. They are too rare to be fully investigated and managed by health professionals. Genetic disorders are caused by change in genes and are often serious and complex. Around the world, most affected individuals are found to be children. They can be progressive and might get worse as children grow older. Niemann-Pick diseases (NPD) is one such group of rare genetic diseases that are characterized by unwanted and abnormal accumulation of lipids within the cells. In this review, we discuss the history, genetic basis, clinical manifestations and diagnostic approaches for NPD. We further discuss the pathophysiology of accumulation of lipids and their impact on cellular functions and organ systems and various management strategies.

Keywords: Rare disease; Genetic mutation; Lipid metabolism; Cholesterol trafficking; Neurological abnormalities   


Full Text:

PDF

References


Vanier MT. Niemann-pick diseases. The Handbook of Clinical Neurology, (2013); 113: 1717-1721.

Kolodny EH. Niemann-Pick disease. Current Opinion in Hematology, (2000); 7(1): 48-52.

Percival BC, Gibson M, Wilson PB, Platt FM, and Grootveld M. Metabolomic studies of lipid storage disorders, with special reference to Niemann-Pick type C disease: A critical review with future perspectives. International

Journal of Molecular Sciences, (2020); 21(7): 2533.

Rodrigues KF, Yong WTL, Bhuiyan MSA, Siddiquee S, Shah MD, and Venmathi Maran BA. Current understanding on the genetic basis of key metabolic disorders: a review. Biology, (2022); 11(9): 1308.

Vitiello L, De Bernardo M, Nuzio SG, Mandato C, Rosa N, Vajro P. Pediatric liver diseases and ocular changes: What hepatologists and ophthalmologists should know and share with each other. Digestive and liver disease, (2020); 52(1): 1-8.

Toledano-Zaragoza A, and Ledesma MD. Addressing neurodegeneration in lysosomal storage disorders: Advances in Niemann Pick diseases. Neuropharmacology, (2020); 171: 107851.

Schuchman EH, Desnick RJ. Types a and B Niemann-pick disease. Molecular Genetics and Metabolism, (2017); 120(1-2): 27-33.

Pfrieger FW. The Niemann-Pick type diseases-A synopsis of inborn errors in sphingolipid and cholesterol metabolism. Progress in Lipid Research, (2023); 90:101225.

Vanier, MT. Niemann-Pick disease type C. Orphanet Journal of Rare Diseases, (2010) 5: 1-18.

Guatibonza Moreno P, Pardo LM, Pereira C, Schroeder S, Vagiri D, et al. At a glance: the largest Niemann-Pick type C1 cohort with 602 patients diagnosed over 15 years. European Journal of Human Genetics, (2023); 31(10): 1108-1116.

Hendriksz CJ, Anheim M, Bauer P, Bonnot O, Chakrapani A, et al. The hidden Niemann-Pick type C patient: clinical niches for a rare inherited metabolic disease. Current Medical Research and Opinion, (2017). 33(5): 877-890.

Patterson M. Niemann-Pick disease type C. University of Washington, Seattle, (2020); 1993-2024.

McGovern MM, Avetisyan R, Sanson B-J, and Lidove O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Current Medical Research and Opinion, (2017); 12(1): 1-13.

Pinto C, Sousa D, Ghilas V, Dardis A, Scarpa M, and Macedo MF Acid sphingomyelinase deficiency: a clinical and immunological perspective. International Journal of Molecular Sciences, (2021); 22(23): 12870.

Zampieri S, Filocamo M, Pianta A, Lualdi S, Gort L, Coll MJ, Sinnott R, Geberhiwot T, Bembi B, Dardis A. SMPD1 mutation update: database and comprehensive analysis of published and novel variants. Human Mutation, (2016) 37(2): 139-147.

Deshpande D, Gupta SK, Sarma AS, Ranganath P, Jain S JMN, et al. Functional characterization of novel variants in SMPD1 in Indian patients with acid sphingomyelinase deficiency. Human Mutation, (2021); 42(10):1336-1350.

Chetta M, Guacci A, Rizzo F, Marchese G, Operto FF, et al. Infantile spasms in early-onset Niemann–Pick disease with a novel compound heterozygous mutations in SMPD1 gene. Elsevier, (2015); 2(6-7): 155-158.

Mukherjee SB, Pandey M, Kapoor S, and Priya TP. Infant with type A Niemann Pick disease and undetectable Niemann Pick cells in bone marrow. Indian Pediatrics, (2012); 49(6): 490.

Reddy JV, Ganley IG, and Pfeffer SR. Clues to neuro-degeneration in Niemann-Pick type C disease from global gene expression profiling. PLoS One, (2006); 1(1): p. e19.

Bernardo A, De Nuccio C, Visentin S, Martire A, Minghetti L, et al. Myelin Defects in Niemann-Pick Type C Disease: Mechanisms and Possible Therapeutic Perspectives. International Journal of Molecular Sciences, (2021);

(16): 8858.

Bulut FD, Bozbulut NE, Özalp Ö, Dalgiç B, Mungan NÖ, et al. Diagnostic value of plasma lysosphingolipids levels in a Niemann-Pick disease type C patient with transient neonatal cholestasis. Journal of Pediatric Endocrinology and Metabolism, (2022); 35(5): 681-685.

Newton J, Palladino EN, Weigel C, Maceyka M, Gräler MH, et al. Targeting defective sphingosine kinase 1 in Niemann–Pick type C disease with an activator mitigates cholesterol accumulation. Journal of Biological Chemistry, (2020); 295(27): 9121-9133.

Djafar JV, Johnson AM, Elvidge KL, and Farrar MA. Childhood dementia: A collective clinical approach to advance therapeutic development and care. Pediatric Neurology, (2023); 139: 76-85.

Cariati I, Masuelli L, Bei R, Tancredi V, Frank C, and D’Arcangelo G. Neurodegeneration in niemann–pick type c disease: An updated review on pharmacological and non-pharmacological approaches to counteract brain and cognitive impairment. International Journal of Molecular Sciences, (2021); 22(12): 6600.

Marchetti M, Faggiano S, & Mozzarelli A. Enzyme replacement therapy for genetic disorders associated with enzyme deficiency. Current Medicinal Chemistry, (2022); 29(3), 489-525.

Garside B, Ho JH, Kwok S, Liu Y, Dhage S, et al. Changes in PCSK 9 and apolipoprotein B100 in Niemann–Pick disease after enzyme replacement therapy with olipudase alfa. Orphanet Journal of Rare Diseases, (2021); 27;16(1):107.

Ryckman AE, Brockhausen I, and Walia, JS. Metabolism of glycosphingolipids and their role in the pathophysiology of lysosomal storage disorders. nternational Journal of Molecular Sciences, (2020); 21(18): 6881.

Zakir F, Mohapatra S, Farooq U, Mirza MA, and Iqbal Z, Introduction to metabolic disorders. Drug Delivery Systems for Metabolic Disorders, (2022); Elsevier.1-20.

Djafar JV, Johnson AM, Elvidge KL, and Farrar MA. Childhood dementia: A collective clinical approach to advance therapeutic development and care. Pediatric Neurology, (2023); 139: 76-85.

Kannan P, Nanda Kumar MP, Rathinam N, Kumar DT, Ramasamy M. Elucidating the mutational impact in causing Niemann–Pick disease type C: an in silico approach. Journal of Biomolecular Structure and Dynamics, (2023); 41(17): 8561-8570.

Dardis A, Zampieri S, Gellera C, Carrozzo R, Cattarossi S, et al. Molecular genetics of Niemann-Pick Type C disease in Italy: an update on 105 patients and description of 18 NPC1 novel variants. Journal of Clinical Medicine, (2020); 9(3): 679.

Xu Y, Zhang Q, Tan L, Xie X, and Zhao Y. The characteristics and biological significance of NPC2: Mutation and disease. Mutation Research – Reviews in Mutation Research, (2019); 782: 108284.

Metcalfe SA. Genetic counselling, patient education, and informed decision-making in the genomic era. Seminars in Fetal and Neonatal Medicine, (2018); 23(2):142-149.

Kumar K, Cowley M, Wetterstrand K, Watson J, Crick F, Sanger F, Nicklen S, et al. Next-generation sequencing and emerging technologies. in Seminars in thrombosis and hemostasis. (2019); Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Sudrié-Arnaud B, Snanoudj S, Dabaj I, Dranguet H, Abily-Donval L, et al. Next-Generation Molecular Investigations in Lysosomal Diseases: Clinical Integration of a Comprehensive Targeted Panel. Diagnostics, (2021); 11(2): 294.

Guan C, Gan X, Yang C, Yi M, Zhang Y, and Liu S. Whole-exome sequencing analysis to identify novel potential pathogenetic NPC1 mutations in two Chinese families with Niemann–Pick disease type C. Neurological Sciences, (2022); 43(6): 3957-3966.

Sitarska D, and Ługowska AJ. Laboratory diagnosis of the Niemann-Pick type C disease: an inherited neurodegenerative disorder of cholesterol metabolism. Metabolic Brain Disease, (2019); 34 (5): 1253-1260.

Hu J, Maegawa GH, Zhan X, Gao X, Wang Y, et al. Clinical, biochemical, and genotype‐phenotype correlations of 118 patients with Niemann‐Pick disease Types A/B. Human Mutation, (2021); 42(5): 614-625.

Cooper J, Church H, Wu HY. Cholestane-3β, 5α, 6β-triol: further insights into the performance of this oxysterol in diagnosis of Niemann-Pick disease type C. Molecular Genetics and Metabolism, (2020); 130(1): 77-86.

Ravanfar P, Syeda W, Rushmore R, Moffat B, Lyall A, et al. Investigation of Brain Iron in Niemann-Pick Type C: A 7T Quantitative Susceptibility Mapping Study. AJNR – American Journal of Neuroradiology, (2023); 44(7): 768-775.

Yang F, Guan Y, Feng X, Rolfs A, Schlüter H, and Luo J. Proteomics of the corpus callosum to identify novel factors involved in hypomyelinated Niemann-Pick Type C disease mice. Molecular Brain, (2019); 12(1): 1-11.

Amin MM. An Introduction, in Handbook of Research on Critical Examinations of Neurodegenerative Disorders. IGI Global, (2019); 195-216.

Masi B, Perles-Barbacaru TA, Bernard M, and Viola A. Clinical and preclinical imaging of hepatosplenic schistosomiasis. Trends in Parasitology, (2020); 36(2): 206-226.

Padungkiatsagul T, Leung L-S, Moss HE. Retinal diseases that can masquerade as neurological causes of vision loss. Current Neurology and Neuroscience Reports, (2020); 20 (11): 51.

Encarnação M, Ribeiro I, David H, Coutinho MF, Quelhas D, et al. Challenges in the Definitive Diagnosis of Niemann–Pick Type C-Leaky Variants and Alternative Transcripts. Genes, (2023); 14(11): 1990.

Lawson J, Harrell E, Deruiter J, Pathak S, Pondugula S, et al. Genetic disease and Niemann-Pick disorders: novel treatments and drug delivery systems. Drug Delivery Systems for Metabolic Disorders, Elsevier, (2022); 161-175.

Pineda M, Walterfang M, and Patterson MC. Miglustat in Niemann-Pick disease type C patients: a review. Orphanet Journal of Rare Diseases, (2018); 13(1): 1-21.

Bonnot O, Klünemann H-H, Velten C, Martin JVT, and Walterfang M. Systematic review of psychiatric signs in Niemann-Pick disease type C. The World Journal of Biological Psychiatry, (2019); 20(4):320-332.

Rego T, Farrand S, Goh AM, Eratne D, Kelso W, et al. Psychiatric and cognitive symptoms associated with Niemann-Pick type C disease: neurobiology and management. CNS Drugs, (2019); 33 (2): 125-142.

Li M. Enzyme replacement therapy: a review and its role in treating lysosomal storage diseases. Pediatric Annals, (2018); 47(5): e191-e197.

Marchetti M, Faggiano S, and Mozzarelli A. Enzyme replacement therapy for genetic disorders associated with enzyme deficiency. Current Medicinal Chemistry, (2022); 29(3): 489-525.

Jones SA, McGovern M, Lidove O, Giugliani R, Mistry PK, et al. Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy. Molecular Genetics and Metabolism, (2020); 131(1-2): 116-123.

Del Grosso A, Parlanti G, Mezzena R, and Cecchini M. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders. Advanced Drug Delivery Reviews, (2022); 114464.

Yue WW, Mackinnon S, and Bezerra GA. Substrate reduction therapy for inborn errors of metabolism. Emerging Topics in Life Sciences, (2019); 3(1): 63-73.

Höller A, Albrecht U, Sigl SB, Zöggeler T, Ramoser G, et al. Successful implementation of classical ketogenic dietary therapy in a patient with Niemann-Pick disease type C. Molecular genetics and metabolism reports, (2021); 27, 100723.

Samaranch L, Pérez-Cañamás A, Soto-Huelin B, Sudhakar V, Jurado-Arjona J, et al. Ledesma MD. Adeno-associated viral vector serotype 9–based gene therapy for Niemann-Pick disease type A. Science Translational Medicine, (2019); 11(506): eaat3738.

Massaro G, Geard AF, Liu W, Coombe-Tennant O, Waddington SN, Baruteau J, Gissen P, Rahim AA. Gene therapy for lysosomal storage disorders: ongoing studies and clinical development. Biomolecules, (2021); 11(4): 611.

Jiang D, Lee H, and Pardridge WM. Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes. Scientific Reports, (2020); 10(1): 13334.

Tran ML, Génisson Y, Ballereau S, and Dehoux CJM. Second-generation pharmacological chaperones: beyond inhibitors. Molecules, (2020); 25(14): 3145.

Du J, Liu X, Zhang Y, Han X, Ma C, et al. The Effects of Combined Therapy With Metformin and Hydroxypropyl-β-Cyclodextrin in a Mouse Model of Niemann-Pick Disease Type C1. Frontiers in Pharmacology, (2022); 12: 825425.

Holzmann C, Witt M, Rolfs A, Antipova V, and Wree A. Gender-specific effects of two treatment strategies in a mouse model of niemann-pick disease type c1. International Journal of Molecular Sciences, (2021); 22(5): 2539.

Kurokawa Y, Osaka H, Kouga T, Jimbo E, Muramatsu K, et al. Gene therapy in a mouse model of niemann–pick disease type C1. Human Gene Therapy, (2021); 32(11-12): 589-598.

Deodato F, Boenzi S, Taurisano R, Semeraro M, Sacchetti E, et al. The impact of biomarkers analysis in the diagnosis of Niemann-Pick C disease and acid sphingomyelinase deficiency. Clinica Chimica Acta, (2018); 486: 387-394.

Jiang X, and Ory D. Advancing diagnosis and treatment of Niemann-Pick C disease through biomarker discovery. Exploration of Neuroprotective Therapy, (2021); 1(3): 146.

Sobrido M-J, Bauer P, De Koning T, Klopstock T, Nadjar Y, Patterson MC, Synofzik M, Hendriksz CJ. Recommendations for patient screening in ultra-rare inherited metabolic diseases: what have we learned from Niemann-Pick disease type C? Orphanet Journal of Rare Diseases, (2019); 14(1): 1-14.

Mengel E, Bembi B, Del Toro M, Deodato F, Gautschi M, et al. Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study. Orphanet Journal of Rare Diseases, (2020); 15 (1): 1-18.

Seaby EG, and Ennis S. Challenges in the diagnosis and discovery of rare genetic disorders using contemporary sequencing technologies. Briefings in Functional Genomics, (2020); 19(4): 243-258.

Hammerschmidt TG, Ribas G. Saraiva-Pereira ML, Bonatto MP, Kessler RG, et al. Molecular and biochemical biomarkers for diagnosis and therapy monitorization of Niemann-Pick type C patients. International Journal of Developmental Neuroscience, (2018); 66: 18-23.

Walterfang M, Di Biase MA, Cropley VL, Scott AM, O'Keefe G, Velakoulis D, Pathmaraj K, Ackermann U, Pantelis C. Imaging of neuroinflammation in adult Niemann-Pick type C disease: A cross-sectional study. Neurology, (2020); 94(16): e1716-e1725.

Eskes EC, Sjouke B, Vaz FM, Goorden SM, Van Kuilenburg AB, et al. Biochemical and imaging parameters in acid sphingomyelinase deficiency: Potential utility as biomarkers. Molecular Genetics and Metabolism, (2020); 130(1): 16-26.

Hammerschmidt TG, Encarnação M, Faverzani JL, de Fátima Lopes F, de Oliveira FP, et al. Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AA. Archives of Biochemistry and Biophysics, (2023); 735: 109510.

Vujosevic S, Parra MM, Hartnett ME, O’Toole L, Nuzzi A, Limoli C, Villani E, Nucci P. Optical coherence tomography as retinal imaging biomarker of neuroinflammation/neurodegeneration in systemic disorders in adults and children. Eye (Lond), 2023. 37(2): 203-219.

Bolukbasi S, Dogan C, Kiykim E, Cakir A, Erden B, et al. Multimodal imaging including optical coherence tomography angiography in patients with type B Niemann-Pick disease. International ophthalmology, (2019); 39: 2545-2552.

Verheul C, Kleijn A, and Lamfers MLJ. Cerebrospinal fluid biomarkers of malignancies located in the central nervous system. Handbook of Clinical Neurology, (2018); 146: 139-169.

Campbell K, Cawley NX, Luke R, Scott KE, Johnson N, et al. Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1. Biomarker Research, (2023); 11(1): 14.

Agrawal N, Farhat NY, Sinaii N, Do AD, Xiao C, et al. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1. Genetics in Medicine, (2023); 25(3): 100349.

De Castro-Oros I, Irún P, Cebolla JJ, Rodriguez-Sureda V, Mallén M, et al. Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: a prospective observational study. Journal of Translational Medicine, (2017); 15 (1): 43.

Degtyareva AV, Proshlyakova TY, Gautier MS, Degtyarev DN, Kamenets EA, et al. Oxysterol/chitotriosidase based selective screening for Niemann-Pick type C in infantile cholestasis syndrome patients. BMC Medical Genetics, (2019); 20 (1): 123.

Papandreou A, Doykov I, Spiewak J, Komarov N, Habermann S, et al. Niemann-Pick type C disease as proof‐of‐concept for intelligent biomarker panel selection in neurometabolic disorders. Developmental Medicine & Child Neurology, (2022); 64(12): 1539-1546.

Maekawa M, Narita A, Jinnoh I, Iida T, Marquardt T, et al. Diagnostic performance evaluation of sulfate-conjugated cholesterol metabolites as urinary biomarkers of Niemann–Pick disease type C. Clinica Chimica Acta, (2019); 494: 58-63.




DOI: http://dx.doi.org/10.62940/als.v11i4.3200

Refbacks

  • There are currently no refbacks.